FunGeST – From Genomics to Therapeutic Targets

Group Leader

Sandra REBOUISSOU
PhD - CR2
Inserm

Projects

“Therapeutic Targets in liver tumors”, led by Sandra Rebouissou Ph.D., develops an integrated approach that extends from the study of the molecular basis of tumor initiation and progression to applications of targeted treatment and the identification of biomarkers predicting the therapeutic response. For this purpose, they develop two main research axes:

1) translational studies based on screening of anti-tumor molecules on large collections of adult and pediatric human liver cancer cell lines characterized extensively at the molecular level, combined with genomic analysis of tumor samples from patients included in clinical trials in order to link tumor molecular alterations and microenvironment to the clinical therapeutic response.

2) basic studies aimed at modeling in cellulo and in vivo the genetic alterations identified in human tumors in order to better identify the driver genes and their role in liver oncogenesis, and to understand the mechanisms of oncogenic cooperations.

Fundings

 

 

 

Team

Sandra REBOUISSOU
PhD - CR2
Inserm
Samantha SCHAEFFER
-
AI Inserm
Anna-Line CALATAYUD
PhD student
MESR Grant
Jill PILET
PhD student
FRM Grant
Massih Ningarhari
MD, PhD student
Fidjie BORDES
AI

Publications

APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, Martin Y, Imbeaud S, Letouzé E, Rebouissou S, Branchereau S, Taque S, Chardot C, Guettier C, Scoazec JY, Fabre M, Brugières L, Zucman-Rossi J. Oncoimmunology. 2019 Mar 28;8(6):e1583547. doi: 10.1080/2162402X.2019.1583547.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S. Gastroenterology. 2019 May 4. pii: S0016-5085(19)36771-X. doi: 10.1053/j.gastro.2019.05.001.

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations. Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP. Cell Metab. 2019 May 7;29(5):1135-1150.e6. doi: 10.1016/j.cmet.2019.01.002. Epub 2019 Jan 31.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J. Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

Note of caution: Contaminations of hepatocellular cell lines. Rebouissou S, Zucman-Rossi J, Moreau R, Qiu Z, Hui L. J Hepatol. 2017 Nov;67(5):896-897. doi: 10.1016/j.jhep.2017.08.002. Epub 2017 Aug 12.

More on Pubmed